Brief: Lyell Immunopharma Strengthens Clinical And Commercial Capabilities With Key Board And Executive Appointments
09/06/2025 21:05
Lyell Immunopharma Inc LYEL.O: LYELL IMMUNOPHARMA STRENGTHENS CLINICAL AND COMMERCIAL CAPABILITIES WITH KEY BOARD AND EXECUTIVE APPOINTMENTS Source text: ID:nGNX35ggvN Further company coverage: LYEL.O
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma